These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1699 related articles for article (PubMed ID: 34477808)
1. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. Klein NP; Lewis N; Goddard K; Fireman B; Zerbo O; Hanson KE; Donahue JG; Kharbanda EO; Naleway A; Nelson JC; Xu S; Yih WK; Glanz JM; Williams JTB; Hambidge SJ; Lewin BJ; Shimabukuro TT; DeStefano F; Weintraub ES JAMA; 2021 Oct; 326(14):1390-1399. PubMed ID: 34477808 [TBL] [Abstract][Full Text] [Related]
2. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572 [TBL] [Abstract][Full Text] [Related]
3. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada. Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115 [TBL] [Abstract][Full Text] [Related]
4. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Goddard K; Lewis N; Fireman B; Weintraub E; Shimabukuro T; Zerbo O; Boyce TG; Oster ME; Hanson KE; Donahue JG; Ross P; Naleway A; Nelson JC; Lewin B; Glanz JM; Williams JTB; Kharbanda EO; Katherine Yih W; Klein NP Vaccine; 2022 Aug; 40(35):5153-5159. PubMed ID: 35902278 [TBL] [Abstract][Full Text] [Related]
5. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976 [TBL] [Abstract][Full Text] [Related]
6. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. Oster ME; Shay DK; Su JR; Gee J; Creech CB; Broder KR; Edwards K; Soslow JH; Dendy JM; Schlaudecker E; Lang SM; Barnett ED; Ruberg FL; Smith MJ; Campbell MJ; Lopes RD; Sperling LS; Baumblatt JA; Thompson DL; Marquez PL; Strid P; Woo J; Pugsley R; Reagan-Steiner S; DeStefano F; Shimabukuro TT JAMA; 2022 Jan; 327(4):331-340. PubMed ID: 35076665 [TBL] [Abstract][Full Text] [Related]
7. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records. Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661 [TBL] [Abstract][Full Text] [Related]
8. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States. Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942 [TBL] [Abstract][Full Text] [Related]
9. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study. Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F; PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992 [TBL] [Abstract][Full Text] [Related]
10. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Faksova K; Walsh D; Jiang Y; Griffin J; Phillips A; Gentile A; Kwong JC; Macartney K; Naus M; Grange Z; Escolano S; Sepulveda G; Shetty A; Pillsbury A; Sullivan C; Naveed Z; Janjua NZ; Giglio N; Perälä J; Nasreen S; Gidding H; Hovi P; Vo T; Cui F; Deng L; Cullen L; Artama M; Lu H; Clothier HJ; Batty K; Paynter J; Petousis-Harris H; Buttery J; Black S; Hviid A Vaccine; 2024 Apr; 42(9):2200-2211. PubMed ID: 38350768 [TBL] [Abstract][Full Text] [Related]
11. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines. Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537 [TBL] [Abstract][Full Text] [Related]
12. Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada. Buchan SA; Alley S; Seo CY; Johnson C; Kwong JC; Nasreen S; Thampi N; Lu D; Harris TM; Calzavara A; Wilson SE JAMA Pediatr; 2023 Apr; 177(4):410-418. PubMed ID: 36848096 [TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. Karlstad Ø; Hovi P; Husby A; Härkänen T; Selmer RM; Pihlström N; Hansen JV; Nohynek H; Gunnes N; Sundström A; Wohlfahrt J; Nieminen TA; Grünewald M; Gulseth HL; Hviid A; Ljung R JAMA Cardiol; 2022 Jun; 7(6):600-612. PubMed ID: 35442390 [TBL] [Abstract][Full Text] [Related]
14. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study. Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759 [TBL] [Abstract][Full Text] [Related]
15. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England. Stowe J; Miller E; Andrews N; Whitaker HJ PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378 [TBL] [Abstract][Full Text] [Related]
16. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Wong HL; Hu M; Zhou CK; Lloyd PC; Amend KL; Beachler DC; Secora A; McMahill-Walraven CN; Lu Y; Wu Y; Ogilvie RP; Reich C; Djibo DA; Wan Z; Seeger JD; Akhtar S; Jiao Y; Chillarige Y; Do R; Hornberger J; Obidi J; Forshee R; Shoaibi A; Anderson SA Lancet; 2022 Jun; 399(10342):2191-2199. PubMed ID: 35691322 [TBL] [Abstract][Full Text] [Related]
17. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J Circulation; 2022 Sep; 146(10):743-754. PubMed ID: 35993236 [TBL] [Abstract][Full Text] [Related]
18. Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans. Dickerman BA; Madenci AL; Gerlovin H; Kurgansky KE; Wise JK; Figueroa Muñiz MJ; Ferolito BR; Gagnon DR; Gaziano JM; Cho K; Casas JP; Hernán MA JAMA Intern Med; 2022 Jul; 182(7):739-746. PubMed ID: 35696161 [TBL] [Abstract][Full Text] [Related]
19. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults. Harris DA; Hayes KN; Zullo AR; Mor V; Chachlani P; Deng Y; McCarthy EP; Djibo DA; McMahill-Walraven CN; Gravenstein S JAMA Netw Open; 2023 Aug; 6(8):e2326852. PubMed ID: 37531110 [TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. Husby A; Hansen JV; Fosbøl E; Thiesson EM; Madsen M; Thomsen RW; Sørensen HT; Andersen M; Wohlfahrt J; Gislason G; Torp-Pedersen C; Køber L; Hviid A BMJ; 2021 Dec; 375():e068665. PubMed ID: 34916207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]